Comparison · NCT03336619-a7c02a98
Nitazoxanide vs Placebo: Number of Subjects Experiencing One or More Complications of Influenza
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nitazoxanide vs Placebo: Number of Subjects Experiencing One or More Complications of Influenza. Trial comparisons, record NCT03336619-a7c02a98. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03336619-a7c02a98
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.159 | 0.123 | 0.204 | wilson | |
| Risk in group 2 | 0.147 | 0.112 | 0.191 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0122 | -0.0449 | 0.069 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.747 | 1.57 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.709 | 1.7 | log | |
| Number needed to treat, for one more participant with the outcome on Nitazoxanide than on Placebo | 82.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nitazoxanide | Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days | 50 | 314 | OG000 |
| Group 2 | Placebo | Two Placebo tablets orally twice daily (b.i.d.) for 5 days | 45 | 306 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Experiencing One or More Complications of Influenza
- Description
Complications of influenza infection included pneumonia, otitis media, bronchitis, sinusitis, worsening of pre-existing health conditions, systemic antibiotic use for infections secondary to influenza infection, hospitalization due to influenza or complications of influenza and death.
- Time frame
- Up to 21 days
- Population
- The ITTI (primary efficacy) population consisted of all subjects positive for influenza by RT-PCR at Baseline
Source ClinicalTrials.gov
Trial
- Title
- A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
- NCT number
- NCT03336619
- Phases
- PHASE3
- Conditions
- Influenza
- Interventions
- Nitazoxanide, Placebo
- Lead sponsor
- Romark Laboratories L.C.
- Results first posted
- 2022-06-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03336619?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03336619-a7c02a98